Джейн Плант Антирак груди



страница31/34
Дата15.05.2016
Размер2.77 Mb.
ТипКнига
1   ...   26   27   28   29   30   31   32   33   34
Journal of Immunoassay , 19 (2–3), 195–207; Schober, D.A. and others, 1990. Perinatal expression of type 1 IGF receptors in porcine small intestine. Endocrinology , 126 (2), 1125–1132.


434 Rao, R.K. and others, 1998. Luminal stability of insulin-like growth factor-1 and -2 in developing rat gastrointestinal tract. Journal of Pediatric Gastroenterology and Nutrition , 26 (2), 179–185.


435 Parisot, J.P. and others, 1999. Altered expression of the insulinlike growth factor-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br. J. Cancer , 79 (5–6), 693–700; Sciacca, L. and others, 1999. Insulin receptor activation by insulin-like growth factor– 2 in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene , 18 (15), 2471–2479; Grothey, A. and others, 1999. The role of insuline-like growth factor and its receptor in cell growth transformation, apoptosis, and chemoresistance In solid tumors. Journal of Cancer Research and Clinical Oncology , 125 (3–4), 166–173; Perks, C. M. and others, 1999. Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of insulin-like growth factor-1 (IGF-1) in human breast cancer cell lines. Br. J. Cancer , 79 (5–6), 701–706; de Cupis, A. and others, 1998. Responsiveness to hormone, growth factor and drug treatment of a human breast cancer cell line; comparison between early and late cultures. In Vitro Cellular and Developmental Biology – Animal , 34 (10), 836–843; Kobari, M. and others, 1998. The inhibitory effect of an epidermal growth factor receptor specific tyrokinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF-1. International Journal of Pancreatology , 24 (2), 85–95; Gooch, J.L. and others, 1998. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res. , 58 (18), 4199–4205; Choki, I. and others, 1998. Osteobiast-derived growth factors enhance adriamycin-cytostasis of MCF-7 human breast cancer cells. Anticancer Res. , 18 (16A), 4213–4224; Jackson, J.G. and others, 1998, Insulin receptor substrate-1 is the predominant signalling molecule activated by insulin-like growth factor-1, insulin, and interleukin– 4 in estrogen receptor-positive human breast cancer cells. Journal of Biological Chemistry , 273 (16), 9994-10 003; Westley, B.R. and others, 1998. Interactions between the oestrogen and IGF signalling pathways in the control of breast epithelial cell proliferation. Biochemical Society Symposium , 63, 35–44; Surmacz, E. and others, 1995. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clinical Cancer Research , 1 (11), 1429–1436.


436 Untersasser, G. and others, 1999. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Experimental Gerontology , 34 (2), 275–287; Xu, Z.D., 1999. Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-2 ribonucleic acid in vitro and in prostate cancer cells. Endocrinology , 140 (5), 2134–2144; Marelli, M.M. and others, 1999. Luteinizing hormone-releasing hormone agonists interfere with the antagonic activity of the insulin-like growth factor system in androgen-dependent prostate cancer cells. Endocrinology , 140 (1), 329–334; Larnharzi, N. and others, 1998. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DY-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor– 2 in tumors. Proc. Natl. Acad. Sci. USA , 95 (15), 8864–8868; Wang, Y.Z. and others, 1998. Sex hormone-induced prostatic carcinogenesis in the noble rat; the role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of cancer. Prostate , 35 (3), 165–177.


437 He, Y., 1999. Comment on the Association between InsulinLike Growth Factor-1 (IGF-I) and Bone Mineral Density: Further Evidence Linking IGF-I to Breast Cancer Risk. Journal of Cellular Endocrinology and Metabolism , 84, 1760.


438 Perks, C. M. and Holly, J.M.P., 2000, Insulin-Like Growth Factor Binding Proteins (IGFBPs) in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia , 5, 75–84.


439 Murphy, M.S. and others, 1998. Growth factors and the gastrointestinal tract. Nutrition , 14 (10), 771–774; Buts, J.F., 1998, Bioactive factors in milk. (in French.) Archives de Pediatrie , 5 (3), 298–306.


440 Shen, W.H. and others, 1998. Stability and distribution of orally administered epidermal growth factor in neonatal pigs. Life Sciences , 63 (10), 809–820; Rao, R.K. and others, 1998. Bovine milk inhibits proteolytic degradation of epidermal growth factor in human gastric and duodenal lumen. Peptides , 19 (3), 495–504; McCuskey, R.S. and others, 1997. Effect of milkborne epidermal growth factor on the hepatic microcirculation and Kupfer cell function in suckling rats. Biology of the Neonate , 7 (3), 202–206; Oguchi, S. and others, 1997. Growth factors in breast milk and their effect on gastrointestinal development. Chang Hua Min Kuo Hsiao Ehr Ko I Hsuek Tsa Chih , 38 (5), 332–337.


441 Salomon, D.S. and others, 1999. Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Bioessays , 21 (1), 61–70; Chou, Y.C. and others, 1999. Induction of mammary carcinomas by N-methyl-N-nitrosurea in ovariectomized rats treated with epidermal growth factor. Carcinogenesis , 20 (4), 677–684; Kurtz, A. and others, 1998. Local control of mammary gland differentiation: mammary-derived growth inhibitor and pleiotrophin. Biochemical Society Symposium , 63, 51–69; Taylor, M.R. and others, 1997. Lactadherin (formerly BA46); a membrane-associated gycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA and Cell Biology , 16 (7), 861–869.


442 Zhau, H.J. and others, 1996. Androgen-depressed phenotype in human prostate cancer. Proc. Natl. Acad. Sci. U.S.A ., 93 (26), 15 152-15 157.


443 Thornburg, W. and others, 1984. Gastrointestinal absorption of epidermal growth factor in suckling rats. American Journal of Physiology , 246, G80-G85.


444 www.prostatepointers.org/cmyers/pf0696.html


445 Gaull, G.E. and others, 1985. Significance of growth modulators in human milk. Pediatrics , 75 (2), 142–145.


446 Delgrange, E. and others, 1997. Sex related differences in the growth of prolacrinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism . 82 (7), 2102–2107.


447 Vonderhaar, B.K., 1998, Prolactin: The forgotten hormone of human breast cancer. Pharmacology and Therapeutics , 79 (2), 169–178; Das, R. and others; 1996. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene , 13 (6), 1139–1145; Mershon, J, and others, 1995. Prolactin is a local growth factor in rat mammary tumors. Endocrinology , 136 (8), 3619–3623; Ginsberg, E. and others, 1995. Prolactin secretion by human breast cancer cells. Cancer Res , 55 (12), 2591–2595; Fuh, G. and others, 1995. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J. Biol Chem , 270 (22), 13 133-13 137.


448 Leav, I. and others, 1999. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. American Journal of Pathology , 154 (3), 863–870; Horti, J. and others, 1998. A phase 2 study of bromocriptine in patients with androgen-independent prostate cancer. Oncology Reports , 5 (4), 893–896; Franklin, R.B. and others, 1997. Prolactin regulation of mitochondrial aspartate aminotransferase and proteinkinase C Molecular and Cellular Endocrinology , 127 (1), 19–25; Janssen, T. and others, 1996. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer , 77 (1), 144–149; Janssen, T. and others, 1995. Organ culture of human tissue as study model of hormonal and pharmacological regulation of benign prostatic hyperplasia and of prostatic cancer, (frans) Acta Urol Belg , 63 (1), 7-14; Oliver, R.T. and others, 1995. New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy. Eur. J. Cancer , 31A (6), 859–860; Rana, A. and others, 1995. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur. J. Cancer , 31A (6), 871–875.


449 Hinuma, S. and others, 1998. A prolactin-releasing peptide in the brain. Nature , 393 (6682), 272–276.


450 Smith, S.S. and others, 1986. Presence of luteinising hormonereleasing hormone (LHRH) in milk. Endocrinol Exp., 2 °C2-3), 147–153; Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J.Nutr., 119 (II), 1543–1551; Nair, R.M. and others, 1987. Studies on LHRH and physiological fluid amino acids in human colostreum and milk. Endocrinolologia Experimentalis , 21 (1), 23–30.


451 White, M.E. and others, 1986. Milk progesterone concentrations following simultaneous administration of buserelin and cloprostenol in cattle with normal corporal lutea. Canadian Journal of Veterinary Research , 50 (2), 285–286; Dinsmore, R.P. and others, 1989. Effect of gonadotropin-releasing hormone on clinical response and fertility in cows with cystyic ovaries, as related to milk progesterone concentration and days after partarition. Journal of the American Veterinary Medical Association, 195 (3), 327–330.


452 Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides in human milk. Am. J. Clin. Nutr., 51 (6), 985–990.


453 Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides inhuman milk. Am. J. Clin. Nutr., 51 (6), 985–990.


454 Flood, J.F. and others, 1991. Increased food intake by neuropeptide Y is due to an increased motivation to eat. Peptides , 12 (6), 1329–1332.


455 Amarant, T. and others, 1982. Luteinising hormone-releasing hormone and thyrotropin-releasing hormone in human and bovine milk. European Journal of Biochemistry , 127 (3), 647–650; Baram, T and others, 1977. Gonadotropin-releasing hormone in milk. Science , 198 (4314), 300–302.


456 Koike, K. and others, 1997. The pituitary folliculo-stellate cell line TtT/GF augments basal and TRH-inducedprolactin secretion by GH3 cells. Life Sci , 61 (25), 2491–2497; Tyson, J.E. and others, 1975. The influence of prolactine secretion on human lactation. J. Clin. Endocrinol Metab , 40 (5), 764–773.


457 Grochowska, R. and others, 1999. Stimulated growth hormone (GH) release in Friesian cattle with respect to GH genotypes. Reproduction Nutrition Development , 39 (2), 171–180; Bourne, R.A. and others, 1977. Serum growth hormone concentrations after growth hormone or thyroid-releasing hormone in cows. Journal of Dairy Science , 60 (10), 1629–1635.


458 Chomczinsky, P. and others, 1993. Stimulatory effect of thyroid hormone on growth hormone gene expression in a human pituitary cell line. J. Clin. Endocrinol Metab , 77 (1), 281–285; Reynolds, A.M., 1991. The effects of chronic exposure to supra physiological concentrations of 3,5,3-triiodo-L-thyronine (T3) on cultured GC cells. Journal of Cellular. Physiology , 149 (3), 544–547.


459 Tenore, A. and others, 1980. Thyroidal response to peroral TSH in suckling and weaned rats. American Journal of Physiology , 238 (5), E428-430.


460 Slebodzinski, A.B. and others, 1998. Triiodothyronine (T3), insulin and characteristics of 5'-monodiodinase (5'-MD) in mare's milk from partarition to 21 days post-partum. Reproduction Nutrition Development , 38 (3), 235–244.


461 Fujimoto, N. and others, 1997. Upregulation of the estrogen receptor by triiodothyronine in rat pituitary cell lines. Journal of Steroid Biochemistry and Molecular Biology , 61 (1–2), 79–85.


462 Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J. Nutr., 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk. (in French.) Arch Pediatr , 5 (3), 298–306.


463 Faulkner, A., 1998. Insulin-like growth factor concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions , 26 (4), S386; Baldini, E. and others, 1994. In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma. Journal of Biological Regulators and Homeostatic Agents , 8 (4), 113–116; Scheven, B.A. and others, 1991. Effects of recombinant human insulin-like growth factor-1 and -2 (IGF) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. Growth Regulation , 1 (4), 160–167; Hodate, K. and others, 1990, Plasma growth hormone, insuline-like growth factor-l, and milk production response to exogenous human growth hormone-releasing factor analogs in dairy cows. Endocrinologia Japonica , 37 (2), 261–273.


464 Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J. Nutr., 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk. (in French.) Arch Pediatr , 5 (3), 298–306.


465 Westrom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. J. Pediatr. Gastroenterol. Nutr., 6 (3), 460–465; Ehman, R. and others, 1985. Bombesin, neurotensin and pro-gamma-melanotropin in immunoreactants in human milk. Regulatory Peptides , 10 (2–3), 99-105.


466 Shutt, D.A. and others, 1985. Comparison of total and free cortisol in bovine serum and milk colostreum. J. Dairy Set , 68 (7), 1832–1834.


467 Vaarala, O. and others, 1998. Cow milk feeding induces antibodies to insulin in children – a link: between cow milk and insulin-dependent diabetes mellitus? Scandinavian Journal of Immunology 47 (2), 131–135; Slebodzinsky, A.B. and others, 1998. Triiodothyronine (T3), insulin and characteristics of 5'-monodiodinase (5'-MD) in mare's milk from partarition to 21 days post-partum. Reprod Nutr Dev , 38 (3), 235–244; Westrom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. J. Pediatr Gastroenterol Nutr., 6 (3), 460–465.


468 Ferrando, T. and others, 1990. Beta-endorphin-like and alpha-MSH-like immunoreactivities in human milk. Life Sci , 47 (7), 633–635.


469 http://www.13.waisays.com/cancer2.htm; Newcomb, P.A. and Egan, K.M., 2006. Dairy food and ovarian cancer risk. The Lancet , March 2006, 797–799; Stang, A. and others, 2006. Adolescent milk fat and galactose consumption and testicular germ cell cancer. Cancer Epidemiology and Biomarkers Prevention , 15, 2189–2195.


470 Maruuchi, T. and others, 1998. Effects of gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo. Japanese Journal of Cancer Research , 89 (9), 977–983; Kuroda, H. and others, 1998. Human chorionic gonadotrophin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of IGF-1 by hCG. Int J. Cancer , 76 (4), 571–578; Kurbacher, C.M. and others, 1995. Influence of luteinising hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biology , 16 (6), 374–384; Manetta, A. and others, 1995. Inhibition of growth of human ovarian cancer in nude mice by luteinising hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertility and Sterility , 63 (2), 282–287.


471 Reiter, E. and others, 1999. Effects of pituitary hormones on the prostate. Prostate , 38 (2), 159–165; Lamharzi, N. and others, 1998. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF– 2 in tumors. Regulatory Peptides , 77 (113), 185–192; Jungwirth, A. and others, 1997. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-2 inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate , 32 (3), 164–172; Maezawa, H. and others, 1997. Potentiating effect of buserelin acetate, an LHRH agonist on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats. Int J. Urol , 4 (4), 411–416; Using, A.W. and others, 1993. Serological precursors of cancer serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev , 2 (1), 27–32; Garde, S. and others, 1993. Effect of prostatic inhibiting peptide on prostate cancer cell growth in vitro and in vivo. Prostate , 7 (2), 183–194.


472 Bosland, M.C., 1996. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Progress in Clinical and Biological Research , 394, 309–352.


473 Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control , 1, 281–284.


474 http://www.who.int


475 Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control , 1. 281–284.


476 http://www.who.int


477 http://www.13.waisays.com/cancer2.htm


478 Underwood, L.E., D'Ercole, J.A. and Van Wyk, J.J., 1980. Somatomedin-C and the assessment of growth. Ped. Clin. N Amer , 27, 4, 771–782, and Perdue, J.F. 1984. Chemistry, structure and function of insulin-like growth factors and their receptors: a review. Can J. Biochem Cell Bio , 62, 1237–1245.


479 http://www.com/healthnews/milk.html


480 Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled «Biology of IGF-I: its interaction with insulin in health and malignant states».


481 Lonning, Per Eystein, 2003. IGF-I and breast cancer. Meeting of the Royal Society of Medicine in London in October 2003, entitled «Biology of IGF-I: its interaction with insulin in health and malignant states».


482 Yee, Doug, 2003. Targeting the IGF system for anti-tumour therapy. Meeting of the Royal Society of Medicine in London in October 2003, entitled «Biology of IGF-I: its interaction with insulin in health and malignant states».


483 Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled «Biology of IGF-I; its interaction with insulin in health and malignant states».


484 Holly, Jeff, 1998. Insulin-like growth factor-1 and new opportunities for cancer prevention. Lancet , 351, 9113, 9 May, 1373–1375.


485 Chan, J.M., Stampfer, M.J., Giovannucci, E. and others, 1998. Plasma insulin-like growth factor-I and prostate cancer risk; a prospective study. Science , 279, 563–566; Harman, S.M., Metter, E.J., Blackmail, M.R., Landis, P.K. and Carter, H.B., 2000. Serum levels of insulin-type growth factor 1 (IGF-I), IGF II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J. Clin. Endocrinol Metab. , 85, 4258–4265; Stattin, P. and nine others, 2000. Plasma insulin-like growth factor-I insulin-like growth-binding proteins, and prostate cancer risk: a prospective study. J. Natl. Cancer Inst. , 92, 1910–1917; Chokkalingam, A.P, and 12 others, 2001. Insulinlike growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. , 10, 421–427; Chan, J.M., Stampfer, M.J., Ma, J. and others, 2002. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl Cancer Inst , 94, 1099–1106; Mantzoros, C.S., Tzonou, A., Signorello, L.B. and others, 1997. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer , 76, 1115–1118; Wolk, A., Mantzoros, C.S., Andersson, S.O. and others, 1998. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl Cancer Inst , 90, 911–915; Holly, J.M.P., Gunnell, D.J. and Davey Smith., G, 1999. Growth hormone, IGF-1 and cancer. Less intervention. Less intervention to avoid cancer? More intervention to prevent cancer. J. Endocrinol , 162, 321–330.


486 Yu, H. and others, 1999. Plasma levels of IGF-I and lung cancer risk, Journal of the National Cancer Institute , 91, 151–156.


487 Ma, J. and others, 2001. Milk intake, circulating levels of IGF-1 and risk of colorectal cancer in men. Journal of the National Cancer Institute , 93 (17), 1330–1336.

1   ...   26   27   28   29   30   31   32   33   34


База данных защищена авторским правом ©dogmon.org 2017
обратиться к администрации

    Главная страница